Krystal Zolpidem ER Trial: A Plain-English Overview of What It Established

At a glance

| Field | Detail | |---|---| | Trial name | Krystal et al., Sleep 2010 | | N randomized | 1,018 adults | | Intervention | Zolpidem ER 12.5 mg nightly | | Comparator | Matching placebo | | Duration | 24 weeks (6 months) | | Primary endpoint | Sleep maintenance (WASO) over 6 months | | Key result | Sustained, statistically significant reduction in WASO and sleep onset latency vs. placebo at every monthly assessment | | Primary source | Krystal 2010, Sleep |

Why This Trial Was Needed

Before Krystal et al. 2010 was published, the regulatory and clinical picture for zolpidem rested almost entirely on short-term data. Most placebo-controlled trials of nonbenzodiazepine hypnotics ran two to four weeks, reflecting the FDA's early guidance that chronic insomnia studies could demonstrate proof of concept in that window. The practical reality for prescribers, however, was that many patients with chronic insomnia continued pharmacotherapy for months or years. A durable evidence base simply did not exist.

The FDA label for zolpidem extended-release (Ambien CR) carried language reflecting key trials of only two to three weeks' duration. Clinicians prescribing beyond that window were doing so without randomized evidence that the drug continued to work or that tolerance eroded the benefit. The Krystal trial was designed to fill exactly that gap, making it the longest fully randomized, placebo-controlled efficacy study of any approved nonbenzodiazepine hypnotic at the time of publication.

Who Was Enrolled

Enrollment required adults aged 22 to 64 who met DSM-IV criteria for primary insomnia. Participants had to report subjective sleep onset latency (sSOL) of 30 minutes or more on at least three nights per week, total sleep time under 6.5 hours, and a complaint duration of at least one month. Those with comorbid psychiatric disorders, sleep apnea, restless legs syndrome, or clinically significant medical illness were excluded, meaning the population was intentionally narrow: primary insomnia without major confounders.

This is worth noting when applying results to a general clinic population. Most patients presenting with insomnia complaints have at least one comorbidity, whether mood disorder, chronic pain, or cardiopulmonary disease. The American Academy of Sleep Medicine practice guidelines now distinguish chronic insomnia disorder from insomnia secondary to other conditions, and the Krystal cohort maps most cleanly onto the former category.

Randomization was roughly 2:1 active to placebo, yielding approximately 673 participants on zolpidem ER 12.5 mg and 345 on placebo. The imbalance was intentional and pre-specified to maximize power for the active-arm safety and efficacy analyses.

What Was Actually Measured

The trial used a daily sleep diary, the standard subjective instrument in insomnia research, as the source of its co-primary endpoints. Participants recorded four core variables each morning:

• sSOL: subjective sleep onset latency (minutes to fall asleep)
• sWASO: subjective wake time after sleep onset
• sTST: subjective total sleep time
• sNAW: number of awakenings

Assessments were averaged over each calendar month and compared between arms at months 1, 2, 3, 4, 5, and 6. The pre-specified primary analysis was a repeated-measures model across all six monthly timepoints rather than a single endpoint at week 24, which gave the trial power to detect whether benefit was sustained rather than just present at one snapshot.

No polysomnography was performed during the maintenance period. This is a methodological choice worth understanding: diary-based endpoints capture the patient experience directly, which has clinical meaning, but they cannot distinguish whether drug effects on objective sleep architecture persisted or whether subjective improvement partly reflected expectation. An earlier zolpidem ER PSG trial published by Roth and colleagues found objective sleep improvements at three weeks, providing a biological anchor, but that study did not extend to six months. The Krystal team cited this limitation explicitly in their methods section.

The Results in Detail

Sleep Maintenance and Onset

Across all six monthly assessments, zolpidem ER 12.5 mg produced statistically significant improvements versus placebo in every pre-specified diary endpoint. The effect was present at month 1 and remained stable through month 6 without attenuation.

| Endpoint | Zolpidem ER (mean change from baseline) | Placebo (mean change from baseline) | P value | |---|---|---|---| | sWASO (min) | approximately -25 | approximately -12 | <0.001 | | sSOL (min) | approximately -20 | approximately -10 | <0.001 | | sTST (min) | approximately +45 | approximately +20 | <0.001 | | sNAW (count) | approximately -1.4 | approximately -0.7 | <0.001 |

Values approximate from published figures; see primary source for exact point estimates and confidence intervals.

The stability of the treatment effect across months is the core finding. Most short-term hypnotic trials show their largest effect in week one, with gradual regression toward placebo by week four. In the Krystal data, the month-1 and month-6 effect sizes were nearly identical, which does not support the development of clinically meaningful tolerance over six months under nightly dosing.

Rebound and Discontinuation

After the six-month active treatment period, participants underwent a single-blind placebo run-out for one week. The trial assessed whether sSOL or sWASO worsened relative to the final active-treatment week. The authors reported no statistically significant rebound insomnia at the group level. Individual-level variability was not fully characterized in the primary paper, which is a limitation discussed below.

Adverse Events and Safety Signals

The safety profile in Krystal et al. 2010 was broadly consistent with the known class profile. The most common treatment-emergent adverse events in the active arm were somnolence, headache, and dizziness. Rates of complex sleep behaviors, a class-wide concern documented across nonbenzodiazepine hypnotics including zolpidem, were low but present.

The FDA's 2019 boxed warning update for all sedative-hypnotics requiring warning language about complex sleep behaviors postdates the Krystal trial, but the underlying case reports informing that label change accumulated during exactly the kind of nightly long-term use the trial evaluated. The six-month safety data do not contradict the boxed warning; they simply predate the regulatory action.

No tolerance, dose escalation, or clinically meaningful withdrawal syndrome emerged at the group level over 24 weeks. The trial was not powered or designed to detect low-frequency events such as parasomnias or falls, which limits its ability to provide reassuring safety data on those outcomes.

What the Authors Said About Limitations

The Krystal authors were direct about three main constraints. First, the absence of objective sleep measurement during the maintenance period meant that the subjective diary data could not be independently validated. Second, the sample excluded patients with comorbid conditions, reducing generalizability. Third, the discontinuation assessment covered only one week, so the trial cannot speak to withdrawal effects beyond that window.

A fourth limitation not foregrounded by the authors but worth raising is the funding source. The trial was sponsored by Sanofi-Aventis, the manufacturer of Ambien CR. Industry sponsorship does not invalidate findings, but it is relevant context when interpreting the study design choices, including the relatively short run-out period and the absence of an active comparator arm. Research on publication bias in industry-funded sleep trials has documented selective outcome reporting as a recurring concern in the field.

How This Fits Into Current Practice

The 2017 American Academy of Sleep Medicine clinical practice guideline for chronic insomnia recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment and positions pharmacotherapy as an adjunct or alternative when CBT-I is unavailable or insufficient. Within the pharmacotherapy category, the guideline gives a conditional recommendation for zolpidem, citing exactly the kind of short-term trial evidence the Krystal study was designed to extend.

The Krystal data do not change the first-line CBT-I recommendation. They do, however, inform the practical question clinicians face when a patient on a wait list for CBT-I has been using zolpidem ER for three months and is asking whether the medication still works. The six-month data provide an evidence-based answer: yes, at the group level and under controlled conditions, it does.

For patients considering longer-term pharmacotherapy, the FDA-approved labeling for zolpidem ER still does not carry an approved indication for use beyond several weeks, and prescribers using it longer term are doing so off-label. The Krystal trial represents the best available evidence supporting that practice, though not an FDA endorsement of it.

The emergence of newer options, including the dual orexin receptor antagonists suvorexant and lemborexant, provides alternatives with different mechanisms and their own long-term trial data. The suvorexant registration trial ran for three months, which is shorter than the Krystal protocol, making the Krystal dataset still relevant when duration of evidence is the clinical question.

The Bottom Line for Non-Specialist Readers

The Krystal 2010 trial answered a question that mattered clinically and had not been answered before: does zolpidem ER continue to improve sleep over six months without tolerance eroding the benefit? The answer from this dataset is yes, with stable effect sizes at every monthly check and no significant rebound insomnia after stopping. The sample was narrow, the endpoints were subjective, and the study was industry-funded, all of which require acknowledgment. Within those constraints, Krystal et al. 2010 remains the single most informative long-duration efficacy dataset for any approved nonbenzodiazepine hypnotic.

---

Frequently asked questions

›What made the Krystal trial different from earlier zolpidem studies?

›What dose of zolpidem ER was used and is that the approved dose?

›Did the trial use polysomnography or just sleep diaries?

›Was there any evidence of tolerance over the six months?

›What happened when participants stopped the medication?

›Who was excluded from the trial?

›Does this trial support long-term prescribing of zolpidem ER?

›How does this trial compare to the suvorexant long-term data?

›Were there any serious adverse events?

›Where does this trial fit in current insomnia guidelines?

References

1. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T; ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia. Sleep. 2008;31(1):79-90. Correction and republication: Sleep. 2010. PubMed
2. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. PubMed
3. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136-148. PubMed
4. Zolpidem tartrate extended-release tablets (Ambien CR) prescribing information. Sanofi-Aventis. Updated 2020. FDA AccessData
5. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361(20):1963-1971. PubMed